NORLIP

Ülke: İsrail

Dil: İngilizce

Kaynak: Ministry of Health

şimdi satın al

Aktif bileşen:

BEZAFIBRATE

Mevcut itibaren:

UNIPHARM LTD, ISRAEL

Farmasötik formu:

TABLETS

Kompozisyon:

BEZAFIBRATE 200 MG

Uygulama yolu:

PER OS

Reçete türü:

Required

Tarafından üretildi:

UNIPHARM LTD, ISRAEL

Terapötik endikasyonlar:

Reduction of elevated blood levels of cholesterol and triglycerides.

Yetkilendirme tarihi:

2021-01-31

Bilgilendirme broşürü

                                PATIENT PACKAGE INSERT IN
ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS )PREPARATIONS( – 1986
The medicine is dispensed with
a doctor’s prescription only
NORLIP
TABLETS
COMPOSITION:
Each NORLIP tablet contains:
Bezafibrate 200 mg
For a list of inactive and allergenic ingredients in
the preparation, please see section 6: “Further
information”. See also section 2: “Important
information about some of the ingredients of
the medicine”.
READ THE LEAFLET CAREFULLY IN ITS ENTIRETY
BEFORE USING THE MEDICINE. This leaflet
contains concise information about the medicine.
If you have further questions, refer to the doctor
or pharmacist.
The medicine has been prescribed to treat your
ailment. Do not pass it on to others. It may harm
them even if it seems to you that their medical
condition is similar.
This preparation is not intended for use in
children.
1. WHAT IS THE MEDICINE INTENDED FOR?
THERAPEUTIC ACTIVITY: to lower the level of
cholesterol and triglycerides )lipids( in the blood,
in cases where dietary treatment alone is not
effective.
THERAPEUTIC GROUP: Fibrates.
2. BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE IF:
• you are sensitive )allergic( to the active
ingredient bezafibrate or to any of the
additional ingredients contained in the
medicine )see section 6(.
• you are sensitive )allergic( to other fibrates or
you have developed sensitivity to sunlight or
artificial light )e.g., tanning beds( during the
treatment with fibrates.
• you are taking medicines from the statin family
)e.g., atorvastatin( and are suffering from the
following conditions, which may increase
the risk of developing a muscle disease
118818010
01B21
)weakness, muscle tissue breakdown or
muscle pain(:
- kidney dysfunction.
- an underactive thyroid )hypothyroidism(.
- severe infection.
- trauma.
- surgery.
- changes in hormone or chemical levels in
your body )seen in blood tests(.
- high alcohol consumption.
• you are being treated with dialysis.
• you have a liver disease.
• you have a gallbladder disease.
• you a
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Bilgilendirme broşürü Bilgilendirme broşürü Arapça 23-11-2021
Bilgilendirme broşürü Bilgilendirme broşürü İbranice 23-11-2021

Bu ürünle ilgili arama uyarıları

Belge geçmişini görüntüleyin